Skip to content

Study · Animal study (in vivo) · 2011

8 results

Anatomical dissociation of melanocortin receptor agonist effects on taste- and gut-sensitive feeding processes.

Baird JP, Palacios M, LaRiviere M, Grigg LA, Lim C, Matute E, Lord J

American journal of physiology. Regulatory, integrative and comparative physiology6 Jul 2011Cited by 4 (Europe PMC)

PMID21734020 (opens in a new tab)PMCIDPMC3197334 (opens in a new tab)DOI10.1152/ajpregu.00577.2010 (opens in a new tab)PepBankPUB-21734020
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Third or fourth ventricle MTII at 0.1 nM and 1 nM significantly reduced 0.8 M sucrose intake.

    In plain wordsIn animals, melanotan II injected into the brain ventricles reduced intake of a sweet sucrose solution.

    Peptide
    Melanotan II
    Outcome
    Decrease0.8 M sucrose intake
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.1 nM and 1 nM · third or fourth ventricleAs given in this study.

    Source sentences

    Summary
    MTII (0.1 nM and 1 nM) delivered to the 3V or 4V significantly reduced 0.8 M sucrose intake.
  2. 02AnimalAnimal study (in vivo)Mechanism

    MTII anorexia was mediated by fewer licking bursts per meal, a lower intrameal ingestion rate and a shorter meal duration.

    In plain wordsIn animals, melanotan II reduced eating through shorter meals and fewer bursts of licking.

    Peptide
    Melanotan II
    Outcome
    DecreaseLicking microstructure after 3V or 4V MTII
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · third or fourth ventricleAs given in this study.

    Source sentences

    Summary
    The anorexia was mediated by reductions in the number of licking bursts in the meal, intrameal ingestion rate, and meal duration
  3. 03AnimalAnimal study (in vivo)Mechanism

    Anorexia after third but not fourth ventricle MTII was associated with a reduced initial lick rate and reduced mean duration of licking bursts, measures linked to taste evaluation.

    In plain wordsIn animals, melanotan II in the forebrain, but not the hindbrain, also slowed early licking, which relates to taste evaluation.

    Peptide
    Melanotan II
    Outcome
    DecreaseInitial lick rate and mean burst duration after 3V MTII
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · third ventricleAs given in this study.

    Source sentences

    Summary
    Anorexia after 3V but not 4V MTII injection was also associated with a reduced rate of licking in the first minute (initial lick rate) and reduced mean duration of licking bursts; these measures have been associated with taste evaluation.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    Third ventricle MTII at 1 nM significantly reduced intake of noncaloric 4 mM saccharin and of 0.1 M and 1 M sucrose solutions.

    In plain wordsIn animals, melanotan II in the forebrain reduced intake of sweet solutions.

    Peptide
    Melanotan II
    Outcome
    DecreaseIntake of saccharin and sucrose solutions after 3V MTII
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 nM · third ventricleAs given in this study.

    Source sentences

    Summary
    3V MTII (1 nM) significantly reduced intake of noncaloric 4 mM saccharin and 0.1 M and 1 M sucrose solutions, but not water.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    Third ventricle MTII at 1 nM did not reduce water intake.

    In plain wordsIn animals, melanotan II in the forebrain did not reduce water intake.

    Peptide
    Melanotan II
    Outcome
    No significant changeWater intake after 3V MTII
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 nM · third ventricleAs given in this study.

    Source sentences

    Summary
    but not water.
  6. 06AnimalAnimal study (in vivo)Mechanism

    The anorexia after third ventricle MTII was again associated with fewer licking bursts and a lower ingestion rate, meal duration, initial lick rate and mean burst duration.

    In plain wordsIn animals, melanotan II again shortened meals and slowed licking when given in the forebrain.

    Peptide
    Melanotan II
    Outcome
    DecreaseLicking microstructure for saccharin and sucrose after 3V MTII
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1 nM · third ventricleAs given in this study.

    Source sentences

    Summary
    The anorexia was again associated with reduced number of licking bursts, ingestion rate, meal duration, initial lick rate, and mean burst duration.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    Licking responses for sucrose were suppressed after third ventricle MTII, but not after fourth ventricle MTII.

    In plain wordsIn animals, melanotan II in the forebrain, but not the hindbrain, reduced licking for sweet sucrose.

    Peptide
    Melanotan II
    Outcome
    DecreaseBrief-access licking for sucrose
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.1 nM and 1 nM · third ventricleAs given in this study.

    Source sentences

    Summary
    Licking responses for sucrose were suppressed, whereas those for quinine solutions were increased after 3V MTII, but not after 4V MTII injections (0.1 nM and 1 nM)
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    Licking responses for bitter quinine solutions were increased after third ventricle MTII, but not after fourth ventricle MTII.

    In plain wordsIn animals, melanotan II in the forebrain, but not the hindbrain, increased licking for bitter quinine.

    Peptide
    Melanotan II
    Outcome
    IncreaseBrief-access licking for bitter quinine
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.1 nM and 1 nM · third ventricleAs given in this study.

    Source sentences

    Summary
    whereas those for quinine solutions were increased after 3V MTII, but not after 4V MTII injections (0.1 nM and 1 nM).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.